Intermittent intraperitoneal dose of teicoplanin in peritoneal dialysis-related peritonitis.
作者信息
Liakopoulos V, Leivaditis K, Nikitidou O, Divani M, Antoniadi G, Dombros N
出版信息
Perit Dial Int. 2012 May-Jun;32(3):365-6. doi: 10.3747/pdi.2011.00171.
Abstract
摘要
相似文献
1
Intermittent intraperitoneal dose of teicoplanin in peritoneal dialysis-related peritonitis.
Perit Dial Int. 2012 May-Jun;32(3):365-6. doi: 10.3747/pdi.2011.00171.
2
Daptomycin in peritoneal dialysis, intraperitoneal or intravenous.
Nefrologia. 2016 Jul-Aug;36(4):461-2. doi: 10.1016/j.nefro.2015.11.001. Epub 2015 Dec 8.
3
4
Effect of Peritoneal Dialysis Fluids on Activity of Teicoplanin Against Methicillin-Resistant Biofilm.
Perit Dial Int. 2019 May-Jun;39(3):293-294. doi: 10.3747/pdi.2018.00168.
5
Treatment of peritonitis in pediatric continuous peritoneal dialysis.
Perit Dial Int. 1999;19 Suppl 2:S450-7.
6
Efficacy and safety of teicoplanin in gram-positive peritonitis in patients on peritoneal dialysis.
J Antimicrob Chemother. 1988 Jan;21 Suppl A:123-31. doi: 10.1093/jac/21.suppl_a.123.
7
Rifampin use in peritoneal dialysis.
Perit Dial Int. 1989;9(4):241-3.
8
Microbiologic aspects of chronic ambulatory peritoneal dialysis.
Kidney Int. 1983 Jan;23(1):83-92. doi: 10.1038/ki.1983.15.
9
Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS).
J Am Soc Nephrol. 1999 Jan;10(1):136-45. doi: 10.1681/ASN.V101136.
10
Ofloxacin solution for persistent exit-site and tunnel infection in peritoneal dialysis.
Perit Dial Int. 2013 Jan-Feb;33(1):101-2. doi: 10.3747/pdi.2012.00070.
引用本文的文献
1
Peritoneal dialysis-related infections recommendations: 2016 update. What is new?
Int Urol Nephrol. 2017 Dec;49(12):2177-2184. doi: 10.1007/s11255-017-1632-9. Epub 2017 Jun 1.
2
ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.
Perit Dial Int. 2016 Sep 10;36(5):481-508. doi: 10.3747/pdi.2016.00078. Epub 2016 Jun 9.
本文引用的文献
1
Peritoneal dialysis-related infections recommendations: 2010 update.
Perit Dial Int. 2010 Jul-Aug;30(4):393-423. doi: 10.3747/pdi.2010.00049.
2
Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis.
Perit Dial Int. 2003 Mar-Apr;23(2):127-31.
3
Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS).
J Am Soc Nephrol. 1999 Jan;10(1):136-45. doi: 10.1681/ASN.V101136.
4
A prospective, randomized trial of two antibiotic regimens in the treatment of peritonitis in CAPD patients: teicoplanin plus tobramycin versus cephalothin plus tobramycin.
J Antimicrob Chemother. 1997 Nov;40(5):729-32. doi: 10.1093/jac/40.5.729.
5
Pharmacokinetic behavior of intraperitoneal teicoplanin during treatment of peritonitis complicating continuous ambulatory peritoneal dialysis.
Antimicrob Agents Chemother. 1996 Aug;40(8):1971-2. doi: 10.1128/AAC.40.8.1971.
Zotero 插件